{"url_path":"/sec/neo/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1077183/0001077183-26-000045-index.html","accession_number":"0001077183-26-000045","cik":"0001077183","ticker":"NEO","issuer_name":"NEOGENOMICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1077183/0001077183-26-000045-index.html","primary_entity_key":"0001077183","primary_entity_name":"NEOGENOMICS INC"},"word_count":185,"has_tables":true,"body_markdown":"Item 8.01Other Events.\n\nAs previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021.\n\nOn June 20, 2026, the Company finalized a civil settlement with the U.S. Department of Justice (“DOJ”), acting on behalf of the OIG-HHS, resolving the U.S. government’s investigation concerning consulting services provided by the Company to certain health care providers, as described above. Pursuant to the terms of the settlement agreement, the Company has agreed to pay $9,813,260 to resolve the matter. As previously disclosed, as of March 31, 2026, the Company had accrued a reserve of $11.2 million for potential damages and liabilities associated with the matters identified during the course of the investigation.\n\nThe settlement agreement is neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded."}